title: New paradigms for therapy for osteosarcoma.
abstract: Osteosarcoma is a primary bone malignancy generally affecting the young, with 60% of cases occurring before the age of 25 years and the peak incidence at 15 years. Survival has improved over the past several decades, with non- metastatic disease having an approximately 70% chance of long-term survival. Unfortunately, patients with metastatic disease at diagnosis or those who have recurrent disease have a dismal prognosis, with approximately 20% surviving long term. In this review article we describe several new therapies in development for osteosarcoma. These include immune-based therapies, strategies to inhibit tumor growth, radiotherapy, and the introduction of new chemotherapies and targets.
authors.affiliation: Pediatric Epidemiology and Clinical Research, University of Minnesota, Mayo Mail Code 484, 420 Delaware Street SE, Minneapolis, MN 55455, USA. nagar003@umn.edu
authors.forename: Rajaram
authors.initials: R
authors.lastname: Nagarajan
authors.forename: Denis
authors.initials: D
authors.lastname: Clohisy
authors.forename: Brenda
authors.initials: B
authors.lastname: Weigel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D007167:Immunotherapy; D012516:Osteosarcoma / Q000276:immunology / Q000628:therapy*; D011878:Radiotherapy
chemical_list: D000970:Antineoplastic Agents